Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Subhasmita Mahapatra, Nisha Amarnath Jonniya, Suman Koirala, Kapil Dattatray Ursal & Parimal Kar. (2023) The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention. Journal of Biomolecular Structure and Dynamics 41:22, pages 13509-13533.
Read now
Read now
Yue Liu, Weiming Lou, Guang Chen, Bing Ding, Jin Kuang, Yize Zhang, Cong Wang, Sainan Duan, Ying Deng & Xiongbing Lu. (2021) Genome-wide screening for the G-protein-coupled receptor (GPCR) pathway-related therapeutic gene RGS19 (regulator of G protein signaling 19) in bladder cancer. Bioengineered 12:1, pages 5892-5903.
Read now
Read now
Rohit K Jain, William Paul Skelton$suffix/text()$suffix/text() & Jingsong Zhang. (2020) Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin. Cancer Management and Research 12, pages 8379-8386.
Read now
Read now
Alberto D’Angelo, Stefan Bagby, Ilaria Camilla Galli, Carlotta Bortoletti & Giandomenico Roviello. (2020) Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. Expert Review of Clinical Pharmacology 13:10, pages 1139-1146.
Read now
Read now
Articles from other publishers (51)
Rabiya Ahsan, Mohd Muazzam Khan, Anuradha Mishra, Gazala Noor & Usama Ahmad. (2023) Protein Kinases and their Inhibitors Implications in Modulating Disease Progression. The Protein Journal 42:6, pages 621-632.
Crossref
Crossref
Tengfei Yuan, Faping Li, Yuchuan Hou & Hui Guo. (2023) Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study. Frontiers in Pharmacology 14.
Crossref
Crossref
Guo-Qing Chen, Hong-Yan Guo, Zhe-Shan Quan, Qing-Kun Shen, Xiaoting Li & Tian Luan. (2023) Natural Products–Pyrazine Hybrids: A Review of Developments in Medicinal Chemistry. Molecules 28:21, pages 7440.
Crossref
Crossref
Cayce Nawaf, Alexander Shiang, Pradeep S. Chauhan, Aadel A. Chaudhuri, Gautum Agarwal & Zachary L. Smith. (2023) Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials. Translational Oncology 37, pages 101763.
Crossref
Crossref
Tyler J. Nielsen, Matthew G. Varga, Catherine T. Cronister, Brian Z. Ring, Robert S. Seitz, Douglas T. Ross, Brock L. Schweitzer & Kimberly McGregor. (2023) The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort. Cancer Immunology, Immunotherapy 72:7, pages 2075-2086.
Crossref
Crossref
Wang He, Changhao Chen, Tianxin Lin, Qian Xu, Chong Ye, Jieyi Du & Jian Huang. (2023) Epidemiology, treatments, and related biomarkers of locally advanced or metastatic urothelial carcinoma in Chinese population: A scoping review. Cancer Medicine 12:14, pages 15384-15403.
Crossref
Crossref
Muhammad Shahzad, Muhammad Nasir Jamil, Hamza Ashraf & Ehsan Ul Islam. (2023) Diagnostic, Therapeutic and Prognostic Implications of Urothelial Carcinoma, A Review. Pakistan Journal of Health Sciences, pages 08-15.
Crossref
Crossref
Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun & Lei Shi. (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Xuexiang Li, Yunxue Li, Bing Liu, Liang Chen, Fang Lyu, Pu Zhang, Qingliu He, Lulin Cheng, Chunyu Liu, Yarong Song & Yifei Xing. (2023)
P4HA2
‐mediated
HIF
‐1α stabilization promotes erdafitinib‐resistance in
FGFR3
‐alteration bladder cancer
. The FASEB Journal 37:4.
Crossref
Crossref
Fabiana Tortora, Evelina La Civita, Pankaj Trivedi, Ferdinando Febbraio, Daniela Terracciano & Amelia Cimmino. (2023) Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers. International Journal of Molecular Sciences 24:5, pages 4601.
Crossref
Crossref
Alexandra Lebedeva, Grigory Timokhin, Ekaterina Ignatova, Alexandra Kavun, Egor Veselovsky, Margarita Sharova, Vladislav Mileyko, Valentina Yakushina, Olesya Kuznetsova, Maria Stepanova, Polina Shilo, Fedor Moiseenko, Nikita Volkov, Igor Plaksa, Andrey Isaev, Margarita Gayryan, Elizaveta Artemyeva, Albina Zhabina, Mikhail Kramchaninov, Valentina Shamrikova, Ilya Pokataev, Alexey Rumyantsev, Evgeny Ledin, Alexey Tryakin, Mikhail Fedyanin & Maxim Ivanov. (2023) Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results. Clinical and Experimental Medicine.
Crossref
Crossref
Jiannan Ren, Haixin Yu, Wei Li, Xin Jin & Bin Yan. (2022) Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer. British Journal of Cancer 128:2, pages 232-244.
Crossref
Crossref
E.M. Oliushina, L.E. Zavalishina, E.Yu. Alekseenok, N.A. Oskina, Yu.Yu. Andreeva, O.A. Kuznetsova, M.L. Filipenko & G.A. Frank. (2023) Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma. Arkhiv patologii 85:2, pages 5.
Crossref
Crossref
Eva-Maria Packeiser, Leila Taher, Weibo Kong, Mathias Ernst, Julia Beck, Marion Hewicker-Trautwein, Bertram Brenig, Ekkehard Schütz, Hugo Murua Escobar & Ingo Nolte. (2022) RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures. Cancer Cell International 22:1.
Crossref
Crossref
Artem Shvartsbart, Jeremy J. Roach, Michael R. Witten, Holly Koblish, Jennifer J. Harris, Maryanne Covington, Rodrigo Hess, Luping Lin, Michelle Frascella, Lisa Truong, Lynn Leffet, Patricia Conlen, Elham Beshad, Ron Klabe, Kamna Katiyar, Laura Kaldon, Ruth Young-Sciame, Xin He, Susan Petusky, Kwang-Jong Chen, April Horsey, Hsiang-Ting Lei, Leslie B. Epling, Marc C. Deller, Oleg Vechorkin & Wenqing Yao. (2022) Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3. Journal of Medicinal Chemistry 65:22, pages 15433-15442.
Crossref
Crossref
Bartosz Małkiewicz, Adam Gurwin, Jakub Karwacki, Krystian Nagi, Klaudia Knecht-Gurwin, Krzysztof Hober, Magdalena Łyko, Kamil Kowalczyk, Wojciech Krajewski, Anna Kołodziej & Tomasz Szydełko. (2022) Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). Cancers 14:21, pages 5286.
Crossref
Crossref
Subham G. Patel, Aday González-Bakker, Ruturajsinh M. Vala, Paras J. Patel, Adrián Puerta, Apoorva Malik, Rakesh K. Sharma, José M. Padrón & Hitendra M. Patel. (2022)
Microwave-assisted multicomponent synthesis of antiproliferative 2,4-dimethoxy-tetrahydropyrimido[4,5-
b
]quinolin-6(7
H
)-ones
. RSC Advances 12:47, pages 30404-30415.
Crossref
Crossref
Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, Sebastian Stintzing & Matthias Ocker. (2022) Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?. Cells 11:19, pages 3180.
Crossref
Crossref
Xinmin Meng, Xue Zhu, Jiali Ji, Hongqin Zhong, Xiyue Li, Hongqing Zhao, Guijuan Xie, Ke Wang, Hong Shu & Xun Wang. (2022) Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor. Molecules 27:19, pages 6733.
Crossref
Crossref
Chiang-Chi Huang, Hui-Ying Liu, Tsuen-Wei Hsu & Wen-Chin Lee. (2022) Updates on the Pivotal Roles of Mitochondria in Urothelial Carcinoma. Biomedicines 10:10, pages 2453.
Crossref
Crossref
Jun Zeng, Kai Ran, Xinyue Li, Longyue Tao, Qiwei Wang, Jiangtao Ren, Rong Hu, Yongxia Zhu, Zhihao Liu & Luoting Yu. (2022) A novel small molecule RK-019 inhibits FGFR2-amplification gastric cancer cell proliferation and induces apoptosis in vitro and in vivo. Frontiers in Pharmacology 13.
Crossref
Crossref
Essam A. Ali, Muzaffar Iqbal, Gamal A. Mostafa, Mohamed R. Alhazani & Yousif A. Asiri. (2022) Ecofriendly, Simple, Fast and Sensitive UPLC-MS/MS Method for Determination of Erdafitinib, a Novel Tyrosine Kinase Inhibitor, in Plasma and Its Application to Metabolic Stability. Applied Sciences 12:17, pages 8625.
Crossref
Crossref
Ting Xu, Weizhang Xu, Yuxiao Zheng, Xiao Li, Hongzhou Cai, Zicheng Xu, Qing Zou & Bin Yu. (2022) Comprehensive FGFR3 alteration-related transcriptomic characterization is involved in immune infiltration and correlated with prognosis and immunotherapy response of bladder cancer. Frontiers in Immunology 13.
Crossref
Crossref
Simone Fabbian, Gabriele Giachin, Massimo Bellanda, Christian Borgo, Maria Ruzzene, Giacomo Spuri, Ambra Campofelice, Laura Veneziano, Marcella Bonchio, Mauro Carraro & Roberto Battistutta. (2022) Mechanism of CK2 Inhibition by a Ruthenium-Based Polyoxometalate. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Jia Zheng, Wei Zhang, Linfeng Li, Yi He, Yue Wei, Yongjun Dang, Shenyou Nie & Zufeng Guo. (2022) Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review. Frontiers in Chemistry 10.
Crossref
Crossref
Brian M. Russell, Leora Boussi & Joaquim Bellmunt. (2022) Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?. Drugs & Aging 39:4, pages 271-284.
Crossref
Crossref
Filipa Amaro, Márcia Carvalho, Maria de Lourdes Bastos, Paula Guedes de Pinho & Joana Pinto. (2022) Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers. Pharmaceuticals 15:3, pages 295.
Crossref
Crossref
Aránzazu González-del-Alba, Antonio José Conde-Moreno, Ana M. García Vicente, Pilar González-Peramato, Estefanía Linares-Espinós & Miguel Ángel Climent. (2022) Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group. Cancers 14:5, pages 1130.
Crossref
Crossref
Anne-Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, Peter De Porre, Anjali Avadhani, Anne O’Hagan, Lilian Y. Li, Daniele Ouellet & Juan Jose Perez Ruixo. (2022) Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. Cancer Chemotherapy and Pharmacology 89:2, pages 151-164.
Crossref
Crossref
Lingzhi Qu, Xiaojuan Chen, Hudie Wei, Ming Guo, Shuyan Dai, Longying Jiang, Jun Li, Sitong Yue, Zhuchu Chen & Yongheng Chen. (2022) Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors. Communications Chemistry 5:1.
Crossref
Crossref
Sarbjit Singh, Divya Utreja & Vimal Kumar. (2021) Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy. Medicinal Chemistry Research 31:1, pages 1-25.
Crossref
Crossref
Rohit Bhatia & Rajesh K. Singh. 2021. Protein Kinases - Promising Targets for Anticancer Drug Research. Protein Kinases - Promising Targets for Anticancer Drug Research.
Xiaohua Sun, Lijun Feng, Chuance Sun & Congmin Kang. (2021) Synthesis of Quinoxaline Derivatives as Intermediates to Obtain Erdafitinib. Pharmaceutical Chemistry Journal 55:9, pages 951-953.
Crossref
Crossref
Rubén López-Cortés, Sergio Vázquez-Estévez, Javier Álvarez Fernández & Cristina Núñez. (2021) Proteomics as a Complementary Technique to Characterize Bladder Cancer. Cancers 13:21, pages 5537.
Crossref
Crossref
Xiaoxia Liang, Pan Wu, Qian Yang, Yunyu Xie, Changliang He, Lizi Yin, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li, Xu Song, Cheng Lv, Wei Zhang & Bo Jing. (2021) An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry 220, pages 113473.
Crossref
Crossref
Juanni Li, Kuan Hu, Jinzhou Huang, Lei Zhou, Yuanliang Yan & Zhijie Xu. (2021) Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment. Aging.
Crossref
Crossref
Yi Li, Lihui Sun, Xiangyang Guo, Na Mo, Jinku Zhang & Chong Li. (2021) Frontiers in Bladder Cancer Genomic Research. Frontiers in Oncology 11.
Crossref
Crossref
Tasuku Matsuoka & Masakazu Yashiro. (2021) Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges. World Journal of Gastrointestinal Oncology 13:5, pages 366-390.
Crossref
Crossref
Eleanor L. Atkinson, Jessica Iegre, Paul D. Brear, Elizabeth A. Zhabina, Marko Hyvönen & David R. Spring. (2021) Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study. Molecules 26:7, pages 1977.
Crossref
Crossref
Sitong Yue, Yukun Li, Xiaojuan Chen, Juan Wang, Meixiang Li, Yongheng Chen & Daichao Wu. (2021) FGFR-TKI resistance in cancer: current status and perspectives. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Javier Torres-Jiménez, Víctor Albarrán-Fernández, Javier Pozas, María San Román-Gil, Jorge Esteban-Villarrubia, Alfredo Carrato, Adriana Rosero, Enrique Grande, Teresa Alonso-Gordoa & Javier Molina-Cerrillo. (2021) Novel Tyrosine Kinase Targets in Urothelial Carcinoma. International Journal of Molecular Sciences 22:2, pages 747.
Crossref
Crossref
Ioannis A. Voutsadakis. (2021) Amplification of 8p11.23 in cancers and the role of amplicon genes. Life Sciences 264, pages 118729.
Crossref
Crossref
Taylor Harris, Ankur Sheel, Yang Zong, Lloyd M. Hutchinson, Kristine M. Cornejo, Lukas Bubendorf, Jennifer Yates & Andrew H. Fischer. (2021) Cytologically targeted next-generation sequencing: a synergy for diagnosing urothelial carcinoma. Journal of the American Society of Cytopathology 10:1, pages 94-102.
Crossref
Crossref
Philipp Erben, Christoph Becker, Igor Tsaur, Matthias B. Stope & Tilman Todenhöfer. (2020) Molekulare Subtypen des Urothelkarzinoms der Harnblase – Hintergründe und klinische RelevanzMolecular subtypes of urothelial carcinoma of the bladder—background and clinical relevance. Der Urologe 60:1, pages 81-88.
Crossref
Crossref
Joseph K. Izes & Seungeun Oh. 2021. Chemotherapy and Immunotherapy in Urologic Oncology. Chemotherapy and Immunotherapy in Urologic Oncology
215
220
.
Margaret A. Knowles. (2020) FGFR3 – a Central Player in Bladder Cancer Pathogenesis?. Bladder Cancer 6:4, pages 403-423.
Crossref
Crossref
Julia López de Andrés, Carmen Griñán-Lisón, Gema Jiménez & Juan Antonio Marchal. (2020) Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Sreevidya Santha, Xiang Ling, Ieman A. M. Aljahdali, Sailee S. Rasam, Xue Wang, Jianqun Liao, Jue Wang, Christos Fountzilas, Qingyong Li, Jun Qu & Fengzhi Li. (2020) Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer. Cancers 12:11, pages 3413.
Crossref
Crossref
Martina Minoli, Mirjam Kiener, George N. Thalmann, Marianna Kruithof-de Julio & Roland Seiler. (2020) Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. International Journal of Molecular Sciences 21:16, pages 5670.
Crossref
Crossref
Wook Jin. (2020) The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Jia-Lian Yang, Charles C. N. Wang, Jia-Hua Cai, Che-Yi Chou, Yu-Chao Lin & Chin-Chuan Hung. (2020) Identification of GSN and LAMC2 as Key Prognostic Genes of Bladder Cancer by Integrated Bioinformatics Analysis. Cancers 12:7, pages 1809.
Crossref
Crossref